Announcing partnership with CityFALCON. Read more (Published: 2017-02-13)

ZYNE - Zynerba Pharmaceuticals Fri 24'th Feb 2017

Industry: Drugs - Generic Sector: Healthcare
Add to Watchlist

Hold/Accumulate

Score: 0.22

#2643 of 5165
Trend:
MV Long:
MV Short:
Pivot:
Volume:
MACD:
Score:
Accuracy: 87.81%
Risk: High
Request Prediction
We need your help. Please answer this short survey to help us improve by clicking HERE.

Stock analysis for Fri 24'th Feb 2017 (Updated daily)

Hold candidate since 2017-02-24

Zynerba Pharmaceuticals Stock Analysis


Zynerba Pharmaceuticals fell by -0.36% in the last day, from USD 22.10 to USD 22.02. The price has risen in 7 of the last 10 days days and is up by 14.99% over the past 2 weeks. Volume increased in the last day by 488 262 shares, but on falling prices. This is may be an early warning and risk is increased slightly for the next couple of days. In total, 869 862 shares bought and sold for approximately USD 19.15 million.

Trend

Zynerba Pharmaceuticals lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 49.3% during the next 3 months and, with 90% probability hold a price between USD 29.21 and USD 39.04 at the end of this period.

Signals

There are mixed signals in the stock today. A sales signal was issued from a pivot top point on Thursday February 23, 2017, which indicates further falls until a new bottom pivot has been found. Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely. Zynerba Pharmaceuticals holds a sales signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock. On further gains, the stock will meet resistance from the short-term moving average at approximately USD 22.04. On a fall, the stock will find some support from the long-term average at approximately USD 19.50. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sales signal.

Relative Strength Index (RSI)

The stock holds a RSI14 at 76 and is currently being overbought on RSI. This does not have to be a sales signal as many stocks may go both long and hard while being overbought on the RSI. It is therefore important to evaluate the history of the share as it may tell you something about the RSI-sensitiveness.

Support & Resistance

Zynerba Pharmaceuticals finds support from accumulated volume at USD 21.23, USD 18.11, and USD 18.03. On the upside the stock meets some resistance just above today's level from accumulated volume at USD 22.46, USD 22.64 and USD 23.00.

The stock is about to test the resistance from accumulated volume at USD 22.46 and this may cause the stock to take a minor break or get into a more sideways move for a few days.

Risk

This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved USD 1.64 between high and low, or 7.50%. For the last week, the stock has had a daily average volatility of 8.10%.

Our recommended stoploss: USD 21.45 (-2.59%) ( criteria: risk and position in trend)

Evaluation

Zynerba Pharmaceuticals holds several positive signals, but we still don't find these to be enough for a buy-recommendation. At the current level we recommend a hold or accumulate position awaiting further development. Due to some small weaknesses in the technical picture we have downgraded our recommendation for this stock since last evaluation from a Buy Candidate to a Hold/Accumulate.

Hold/Accumulate


Want to start trading like a professional?

Access Portfolios Now!

Want to be one step ahead of others?

Subscribe Now!

Click for pro features list

Chart Explanation

Build Your Watchlist

Add ZYNE My Watchlist

Weekly Trading Secrets

Recommended
book of the week

Sign up to get FREE access to all of our features

Auto-portfolios that gain up to 30%

Request predictions from other users

Watchlist builder with notifications

Get rid of this notification!

Sign up / Log in
5165
Companies analyzed today